The role of neuropilins in cancer

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1099-1107

  Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; HISTONE DEACETYLASE INHIBITOR; NEUROPILIN 1; NEUROPILIN 2; PROTEIN ANTIBODY; SEMAPHORIN 3A; THALIDOMIDE; TRICHOSTATIN A; TYROSINE KINASE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VORINOSTAT;

CANCER CELL; CANCER CLASSIFICATION; CANCER GROWTH; COLON CANCER; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEUROPILINS; SIGNAL TRANSDUCTION;

EID: 33745063095     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0538     Document Type: Review

References (111)

1. Kitsukawa T, Shimizu M, Sanbo M, et al. Neuropilin-semaphorin III/ D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 1997;19:995-1005.
2. Chen H, Bagri A, Zupicich JA, et al. Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections. Neuron 2000;25:43-56.
3. Giger RJ, Cloutier JF, Sahay A, et al. Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron 2000;25:29-41.
4. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 1997;90:739-51.
5. Rochlin MW, Farbman AI. Trigeminal ganglion axons are repelled by their presumptive targets. J Neurosci 1998;18:6840-52.
6. Chedotal A, Del Rio JA, Ruiz M, et al. Semaphorins III and IV repel hippocampal axons via two distinct receptors. Development 1998;125: 4313-23.
7. Kolodkin AL, Levengood DV, Rowe EG, et al. Neuropilin is a semaphorin III receptor. Cell 1997;90:753-62.
8. Soker S, Fidder H, Neufeld G, et al. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;27:5761-7.
9. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
10. Broholm H, Laursen H. Vascular endothelial growth factor (VEGF) receptor neuropilin-1's distribution in astrocytic tumors. APMIS 2004; 112:257-63.
11. Stephenson JM, Banerjee S, Saxena NK, et al. Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 2002;101:409-14.
12. Fakhari M, Pullirsch D, Abraham D, et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 2002;94:258-63.
13. Straume O, Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003;6:295-301.
14. Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol 2004; 28:347-56.
15. Lantuejoul S, Constantin B, Drabkin H, et al. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003;200:336-47.
16. Kawakami T, Tokunaga T, Hatanaka H, et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 2002;95:2196-201.
17. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M. Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 2004;10:581-90.
18. Parikh AA, Liu WB, Fan F, et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003;98:720-9.
19. Vanveldhuizen PJ, Zulfiqar M, Banerjee S, et al. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol Rep 2003;10:1067-71.
20. Latil A, Bieche I, Pesche S, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer 2000;89:167-71.
21. Parikh AA, Fan F, Liu WB, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004;164:2139-51.
22. Ding H, Wu X, Roncari L, et al. Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer 2000;88:584-92.
23. Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics 2000;70:211-22.
24. Gluzman-Poltorak Z, Cohen T, Herzog Y, et al. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 2000;275:18040-5.
25. Nakamura F, Goshima Y. Structural and functional relations of neuropilins. In: Bagnard D, editor. Adhesion molecules. Georgetown (TX): Landes Bioscience; 2002.
26. Bork P, Beckman G. The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol 1993;231:539-45.
27. Gu C, Limberg BJ, Whitaker GB, et al. Characterization of neuropilin-1 structural features that confer binding to sernaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002;277:18069-76.
28. Renzi MJ, Feiner L, Koppel AM, Raper JA. A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1. J Neurosci 1999;19:7870-80.
29. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 1999; 19:6519-27.
30. Bachelder RE, Lipscomb EA, Lin X, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003;63:5230-3.
31. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004;114:1260-71.
32. Castro-Rivera E, Ran S, Thorpe P, et al. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 2004;101:11432-7.
33. Nasarre P, Constantin B, Rouhaud L, et al. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia 2003;5:83-92.
34. Gluzman-Poltorak Z, Cohen T, Shibuya M, et al. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 2001;276:18688-94.
35. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 2001;98: 12677-82.
36. Makinen T, Olofsson B, Karpanen T, et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 1999;274:21217-22.
37. Migdal M, Huppertz B, Tessier S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8.
38. West DC, Chris RG, Duchesne L, et al. Interactions of multiple heparin-binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem 2005;280:13457-64.
39. Brambilla E, Constantin B, Drabkin H, et al. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. Am J Pathol 2000;156:939-50.
40. Tomizawa Y, Sekido Y, Kondo M, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A 2001;98: 13954-9.
41. Miao HQ, Soker S, Feiner L, et al. Neuropilin-1 mediates collapsin-1/ semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999;146:233-42.
42. Gagnon ML, Bielenberg DR, Gechtman Z, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci U S A 2000; 97:2573-8.
43. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23: 1011-27.
44. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
45. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
46. Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993;133:848-59.
47. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
48. Nakamura F, Tanaka M, Takahashi T, et al. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 1998;21:1093-100.
49. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999;99:71-80.
50. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M. Inhibition of vascular endothelial growth factor (VEGF)-induced enothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 1997;272:31582-8.
51. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996;271:5638-46.
52. Soker S, Miao HQ, Nomi M, et al. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002;85:357-68.
53. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine Growth Factor Rev 2005;16:535-48.
54. Rollin S, Lemieux C, Maliba R, et al. VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood 2004;103:3789-97.
55. Bernatchez PN, Rollin S, Soker S, et al. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: role of neuropilin-1. J Cell Biochem 2002;85:629-39.
56. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 2001;276:25520-31.
57. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000;275:26690-5.
58. Wang L, Zang H, Wang P, et al. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 2003;278:48848-60.
59. Murga M, Fernandez-Capetillo O, Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005;105:1992-9.
60. Li M, Yang H, Chai H, et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 2004;101:2341-50.
61. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-40.
62. Barr MP, Byrne AM, Duffy AM, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer 2005;92:328-33.
63. Beierle EA, Dai W, Langham MRJ, et al. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004;119:56-65.
64. Kawakami A, Kitsukawa T, Takagi S, Fujisawa H. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. J Neurobiol 1996;29:1-17.
65. Takagi S, Tsuji T, Amagai T, et al. Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol 1987;122:90-100.
66. Takagi S, Kasuya Y, Shimizu M, et al. Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system. Dev Biol 1995;170:207-22.
67. Furumatsu T, Shen ZN, Kawai A, et al. Vascular endothelial growth factor principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. J Biochem (Tokyo) 2003;133:633-9.
68. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002;30:472-7.
69. Cohen T, Gluzman-Poltorak Z, Brodzky A, et al. Neuroendocrine cells along the digestive tract express neuropilin-2. Biochem Biophys Res Commun 2001;284:395-403.
70. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002;3:477-82.
71. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-46.
72. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002;63:1133-48.
73. Belaid Z, Hubint F, Humblet C, et al. Differential expression of vascular endothelial growth factor and its receptors in hematopoietic and fatty bone marrow: evidence that neuropilin-1 is produced by fat cells. Haematologica 2005;90:400-1.
74. Tordjman R, Ortega N, Coulombel L, et al. Neuropilin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells? Blood 1999;94:2301-9.
75. Thomas S, Vanuystel J, Gruden G, et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000;11:1236-43.
76. Harper SJ, Xing CY, Whittle C, et al. Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. Clin Sci (Lond) 2001;101:439-46.
77. Bron R, Eickholt BJ, Vermeren M, Fragale N, Cohen J. Functional knockdown of neuropilin-1 in the developing chick nervous system by siRNA hairpins phenocopies genetic ablation in the mouse. Dev Dyn 2004; 230:299-308.
78. Cloutier JF, Giger RJ, Koentges G, Dulac C, Kolodkin AL, Ginty DD. Neuropilin-2 mediates axonal fasciculation, zonal segregation, but not axonal convergence, of primary accessory olfactory neurons. Neuron 2002;33:877-92.
79. Kawasaki T, Bekku Y, Suto F, et al. Requirement of neuropilin 1-mediated Sema3A signals in patterning of the sympathetic nervous system. Development 2002;129:671-80.
80. Walz A, Rodriguez I, Mombaerts P. Aberrant sensory innervation of the olfactory bulb in neuropilin-2 mutant mice. J Neurosci 2002;22: 4025-35.
81. Pozas E, Pascual M, Nguyen Ba-Charvet KT, et al. Age-dependent effects of secreted Semaphorins 3A, 3F, and 3E on developing hippocampal axons: in vitro effects and phenotype of Semaphorin 3A (-/-) mice. Mol Cell Neurosci 2001;18:26-43.
82. Rochlin MW, O'Connor R, Giger RJ, Verhaagen J, Farbman AI. Comparison of neurotrophin and repellent sensitivities of early embryonic geniculate and trigeminal axons. J Comp Neurol 2000;422:579-93.
83. Yang H, Li M, Chai H, et al. Effects of cyclophilin A on cell proliferation and gene expressions in human vascular smooth muscle cells and endothelial cells. J Surg Res 2005;123:312-9.
84. Zhang ZG, Tsang W, Zhang L, et al. Up-regulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat. J Cereb Blood Flow Metab 2001;21:541-9.
85. Oh H, Takagi H, Otani A, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Aced Sci U S A 2002;99: 383-8.
86. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its coreceptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998;273:22128-35.
87. Yang H, Li M, Chai H, et al. Expression and regulation of neuropilins and VEGF receptors by TNF-α in human endothelial cells. J Surg Res 2004; 122:249-55.
88. Teruyama K, Abe M, Nakano T, et al. Neurophilin-1 is a downstream target of transcription factor Ets-1 in human umbilical vein endothelial cells. FEES Lett 2001;504:1-4.
89. Yamagishi H, Olson EN, Srivastava D. The basic helix-loop-helix transcription factor, dHAND, is required for vascular development. J Clin Invest 2000;105:261-70.
90. Takashima S, Kitakaze M, Asakura M, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Aced Sci U S A 2002;99: 3657-62.
91. Kawasaki T, Kitsukawa T, Bekku Y, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999;126: 4895-902.
92. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002;129:4797-806.
93. Serini G, Valdembri D, Zanivan S, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003;424: 391-7.
94. Fons P, Herault JP, Delesque N, et al. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 2004;200:351-9.
95. Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 2005;280: 9904-12.
96. Kessler O, Shraga-Heled N, Lange T, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 2004;64:1008-15.
97. Chen H, Chedotal A, He Z, et al. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron 1997;19:547-59.
98. Giger RJ, Urquhart ER, Gillespie SK, et al. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998;21:1079-92.
99. Miao HQ, Lee P, Lin H, et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14: 2532-9.
100. Gray MJ, Way JS, Belcheva A, et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 2005;65:3664-70.
101. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003; 163:505-16.
102. Jogi A, Vallon-Christersson J, Holmquist L, et al. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res 2004;295: 469-87.
103. Akagi M, Kawaguchi M, Liu W, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 2003;88:796-802.
104. Nasarre P, Kusy S, Constantin B, et al. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin mediated cell adhesion. Neoplasia 2005;7:180-9.
105. Hazan RB, Qiao R, Keren R, et al. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004;1014:155-63.
106. Bachelder RE, Wendt MA, Mercurio AM, et al. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62: 7203-6.
107. Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 2005;104:427-38.
108. Wey JS, Gray MJ, Fan F, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 2005;93:233-41.
109. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21:427-36.
110. Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood 2005; 106:125-34.
111. Qi L, Robinson WA, Brady BMR, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res 2003;23:3917-22.